Neurocrine Biosciences, Inc. announced top-line data from its Phase 4 KINECT-PRO study, demonstrating clinically meaningful and sustained effects of INGREZZA capsules on the physical, social, and emotional impacts experienced by patients living with tardive dyskinesia (TD). These improvements were observed irrespective of TD severity or underlying psychiatric condition.
KINECT-PRO is the first study to show patient-reported impact of a vesicular monoamine transporter 2 inhibitor, specifically INGREZZA, on TD using multiple clinically validated scales, including the Tardive Dyskinesia Impact Scale. Improvements were observed as early as four weeks at the lowest dose of 40 mg, and the safety and tolerability profile was consistent with previous findings.
The study's primary objective evaluated changes in patient-reported physical and socio-emotional impacts, as well as overall sense of health and well-being. The results provide a more complete perspective on a patient's experience, highlighting the broad range of improvements following treatment with INGREZZA.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.